Thursday, May 09, 2024
Biolabs International LLC proudly announces an exclusive partnership with Watmind USA™, marking a significant advancement in diagnostics.
This collaboration introduces the SpeedySwab™ COVID-19 + FLU A&B Antigen Test, addressing the pressing need for accurate Point of Care (POC) testing.
The year 2024 signifies a transformative moment in diagnostics, with the emergence of innovative 3-in-1 tests capable of detecting COVID-19 + FLU A&B.
Biolabs International LLC, renowned for its commitment to excellence, solidifies its industry leadership by securing this exclusive partnership with Watmind USA™.
Biolabs International LLC is dedicated to delivering top-tier products to its clientele.
With FDA/EUA 230037 approval granted, the SpeedySwab™ Rapid COVID-19 + FLU A&B Antigen Test stands as a beacon of accuracy and dependability, empowering global efforts in combating infectious diseases.
source: prnewswire.com
